Cargando…

What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population

BACKGROUND: Debate on pricing and reimbursement of cancer medicines highlights the need to establish the value of cancer medicines. OBJECTIVE: This study aims to elicit the trade-offs in cancer medicine characteristics that the Belgian population is willing to make. METHODS: A discrete choice experi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pauwels, Kim, Huys, Isabelle, Casteels, Minne, Denier, Yvonne, Vandebroek, Martina, Simoens, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885509/ https://www.ncbi.nlm.nih.gov/pubmed/31359269 http://dx.doi.org/10.1007/s40258-019-00504-4

Ejemplares similares

Financial based agreements and performance based agreements: the Belgian experience
por: Pauwels, Kim, et al.
Publicado: (2015)

Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory study
por: De Weerdt, Elfi, et al.
Publicado: (2017)

Drug shortages in European countries: a trade-off between market attractiveness and cost containment?
por: Pauwels, Kim, et al.
Publicado: (2014)

Insights into European Drug Shortages: A Survey of Hospital Pharmacists
por: Pauwels, Kim, et al.
Publicado: (2015)

Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs
por: Pauwels, Kim, et al.
Publicado: (2016)

Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future
por: Pauwels, Kim, et al.
Publicado: (2017)

Toward a European definition for a drug shortage: a qualitative study
por: De Weerdt, Elfi, et al.
Publicado: (2015)

Time Investment in Drug Supply Problems by Flemish Community Pharmacies
por: De Weerdt, Elfi, et al.
Publicado: (2017)

How to Value Orphan Drugs? A Review of European Value Assessment Frameworks
por: Blonda, Alessandra, et al.
Publicado: (2021)

Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012
por: Pauwels, Kim, et al.
Publicado: (2017)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
por: Vandenplas, Yannick, et al.
Publicado: (2022)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice
por: Janssens, Rosanne, et al.
Publicado: (2018)

Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives
por: van Overbeeke, Eline, et al.
Publicado: (2020)

Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study
por: Abdallah, Khadidja, et al.
Publicado: (2022)

Sharing of Clinical Trial Data and Samples: The Cancer Patient Perspective
por: Broes, Stefanie, et al.
Publicado: (2020)

Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
por: Barbier, Liese, et al.
Publicado: (2021)

Call for a Dedicated European Legal Framework for Bacteriophage Therapy
por: Verbeken, Gilbert, et al.
Publicado: (2014)

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
por: Dutta, Binita, et al.
Publicado: (2019)

Assessment of Methodological Quality of Economic Evaluations in Belgian Drug Reimbursement Applications
por: Simoens, Steven
Publicado: (2013)

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
por: Vandenplas, Yannick, et al.
Publicado: (2021)

What matters most to patients with multiple myeloma? A Pan-European patient preference study
por: Janssens, Rosanne, et al.
Publicado: (2022)

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
por: Moorkens, Evelien, et al.
Publicado: (2020)

R&D Costs of New Medicines: A Landscape Analysis
por: Simoens, Steven, et al.
Publicado: (2021)

Emerging Insights into European Markets of Biologics, Including Biosimilars
por: Simoens, Steven, et al.
Publicado: (2022)

Establishing a Belgian Nutrition Society (BNS): Filling the Void
por: Cani, Patrice, et al.
Publicado: (2009)

Off-label use of orphan medicinal products: a Belgian qualitative study
por: Dooms, Marc, et al.
Publicado: (2016)

Correction: Establishing a Belgian Nutrition Society (BNS): Filling the Void
por: Cani, Patrice, et al.
Publicado: (2023)

By Belgians for Belgians
por: Childers, M. A.
Publicado: (1915)

What can the CF registry tell us about rare CFTR-mutations? A Belgian study
por: De Wachter, E., et al.
Publicado: (2017)

What, who and when? Incorporating a discrete choice experiment into an economic evaluation
por: Tinelli, Michela, et al.
Publicado: (2016)

Parents’ and Teachers’ Opinions about the School Food Policy in Belgian Flemish Nursery Schools
por: Vereecken, Carine, et al.
Publicado: (2009)

Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines
por: Vandenplas, Yannick, et al.
Publicado: (2022)

Development and implementation of “Check of Medication Appropriateness” (CMA): advanced pharmacotherapy-related clinical rules to support medication surveillance
por: Quintens, Charlotte, et al.
Publicado: (2019)

What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis
por: Díaz-Torné, Cesar, et al.
Publicado: (2020)

What influenza vaccination programmes are preferred by healthcare personnel? A discrete choice experiment
por: Liao, Qiuyan, et al.
Publicado: (2020)

What are healthcare workers’ preferences for hand hygiene interventions? A discrete choice experiment
por: Chen, Wenlin, et al.
Publicado: (2021)

What Tinnitus Therapy Outcome Measures Are Important for Patients?– A Discrete Choice Experiment
por: Rademaker, Maaike M., et al.
Publicado: (2021)

Does Allulose Appeal to Consumers? Results from a Discrete Choice Experiment in Germany
por: Jürkenbeck, Kristin, et al.
Publicado: (2022)

The Value of Preventative Dental Care: A Discrete-Choice Experiment
por: Boyers, D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lvgi3lt63rtlbj9b6h028rdr1f